Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Comments on Motamedi G, Meador K. Epilepsy and cognition. Epilepsy & behavior 2003;4:S25-S28.

Busch RM.

Epilepsy Behav. 2014 Nov;40:26-8. doi: 10.1016/j.yebeh.2014.08.021. Epub 2014 Oct 11. No abstract available.

2.

Cognitive Effects of Low-dose Topiramate Compared with Oxcarbazepine in Epilepsy Patients.

Kim SY, Lee HW, Jung DK, Suh CK, Park SP.

J Clin Neurol. 2006 Jun;2(2):126-33. doi: 10.3988/jcn.2006.2.2.126. Epub 2006 Jun 20.

3.

Delirium in older emergency department patients: recognition, risk factors, and psychomotor subtypes.

Han JH, Zimmerman EE, Cutler N, Schnelle J, Morandi A, Dittus RS, Storrow AB, Ely EW.

Acad Emerg Med. 2009 Mar;16(3):193-200. doi: 10.1111/j.1553-2712.2008.00339.x. Epub 2009 Jan 20.

4.

Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake.

Roe CM, Mintun MA, D'Angelo G, Xiong C, Grant EA, Morris JC.

Arch Neurol. 2008 Nov;65(11):1467-71. doi: 10.1001/archneur.65.11.1467.

5.

Predisposing and precipitating factors for delirium in a frail geriatric population.

Laurila JV, Laakkonen ML, Tilvis RS, Pitkala KH.

J Psychosom Res. 2008 Sep;65(3):249-54. doi: 10.1016/j.jpsychores.2008.05.026. Review. Erratum in: J Psychosom Res. 2008 Nov;65(5):507. Laurila, Jouko Valdemar [removed]; Timo, Strandberg E [removed]; Reijo, Tilvis S [corrected to Tilvis, Reijo S]; Pitkala, Kaisu H [added].

PMID:
18707947
6.

Topiramate in older patients with partial-onset seizures: a pilot double-blind, dose-comparison study.

Ramsay RE, Uthman B, Pryor FM, Rowan AJ, Bainbridge J, Spitz M, Sirven JI, Frederick TE.

Epilepsia. 2008 Jul;49(7):1180-5. doi: 10.1111/j.1528-1167.2008.01584.x.

7.

Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate.

Shank RP, Maryanoff BE.

CNS Neurosci Ther. 2008 Summer;14(2):120-42. doi: 10.1111/j.1527-3458.2008.00041.x. Review.

PMID:
18482025
8.

Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies.

Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, Leppik IE, Tomson T, Perucca E.

Epilepsia. 2008 Jul;49(7):1239-76. doi: 10.1111/j.1528-1167.2008.01561.x.

9.

Epilepsy outcomes in elderly treated with topiramate.

Stefan H, Hubbertz L, Peglau I, Berrouschot J, Kasper B, Schreiner A, Krimmer J, Schauble B; TOP-GER-13.

Acta Neurol Scand. 2008 Sep;118(3):164-74. doi: 10.1111/j.1600-0404.2008.01018.x. Epub 2008 Mar 31.

PMID:
18384458
10.

Analysis of safety and tolerability data obtained from over 1,500 patients receiving topiramate for migraine prevention in controlled trials.

Adelman J, Freitag FG, Lainez M, Shi Y, Ascher S, Mao L, Greenberg S, Hulihan J.

Pain Med. 2008 Mar;9(2):175-85. doi: 10.1111/j.1526-4637.2007.00389.x.

PMID:
18298700
11.

Relative influences of adjunctive topiramate and adjunctive lamotrigine on scanning and the effective field of view.

Mills KC, Drazkowski JF, Hammer AE, Caldwell PT, Kustra RP, Blum DE.

Epilepsy Res. 2008 Feb;78(2-3):140-6. Epub 2007 Dec 21. Erratum in: Epilepsy Res. 2009 Sep;86(1):99.

PMID:
18155445
12.

Education delays accelerated decline on a memory test in persons who develop dementia.

Hall CB, Derby C, LeValley A, Katz MJ, Verghese J, Lipton RB.

Neurology. 2007 Oct 23;69(17):1657-64.

PMID:
17954781
13.

Increased propensity for calcium phosphate kidney stones with topiramate use.

Vega D, Maalouf NM, Sakhaee K.

Expert Opin Drug Saf. 2007 Sep;6(5):547-57. Review.

PMID:
17877442
14.

Long-term effects of levetiracetam and topiramate in clinical practice: A head-to-head comparison.

Bootsma HP, Ricker L, Diepman L, Gehring J, Hulsman J, Lambrechts D, Leenen L, Majoie M, Schellekens A, de Krom M, Aldenkamp AP.

Seizure. 2008 Jan;17(1):19-26. Epub 2007 Jul 6.

15.

Negative effects of antiepileptic drugs on mood in patients with epilepsy.

Mula M, Sander JW.

Drug Saf. 2007;30(7):555-67. Review.

PMID:
17604407
16.

The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial.

Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, Cramp C, Cockerell OC, Cooper PN, Doughty J, Eaton B, Gamble C, Goulding PJ, Howell SJ, Hughes A, Jackson M, Jacoby A, Kellett M, Lawson GR, Leach JP, Nicolaides P, Roberts R, Shackley P, Shen J, Smith DF, Smith PE, Smith CT, Vanoli A, Williamson PR; SANAD Study group.

Lancet. 2007 Mar 24;369(9566):1016-26.

17.

Suicidality and antiepileptic drugs: is there a link?

Kalinin VV.

Drug Saf. 2007;30(2):123-42. Review.

PMID:
17253878
18.

Topiramate-positive death-investigation and impaired-driving cases in Washington State.

Gordon AM, Logan BK.

J Anal Toxicol. 2006 Oct;30(8):599-602.

PMID:
17132258
19.

Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?

Johannessen SI, Tomson T.

Clin Pharmacokinet. 2006;45(11):1061-75. Review.

PMID:
17048972
20.

Biochemical and stone-risk profiles with topiramate treatment.

Welch BJ, Graybeal D, Moe OW, Maalouf NM, Sakhaee K.

Am J Kidney Dis. 2006 Oct;48(4):555-63.

PMID:
16997051

Supplemental Content

Support Center